187 related articles for article (PubMed ID: 26172931)
1. Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study.
Kosmas IP; Kitsou C; Lazaros L; Markoula S; Peschos D; Mynbaev O; Tournaye H; Prapas N; Prapas I; Zikopoulos A; Galani V; Georgiou I
Gynecol Endocrinol; 2015; 31(9):702-7. PubMed ID: 26172931
[TBL] [Abstract][Full Text] [Related]
2. The combination of Everolimus with Verapamil reduces ovarian weight and vascular permeability on ovarian hyperstimulation syndrome: a preclinical experimental randomized controlled study.
Kitsou C; Kosmas I; Lazaros L; Tzallas C; Tinelli A; Mynbaev O; Prapas N; Prapas I; Dalkalitsis A; Georgiou I
Gynecol Endocrinol; 2016 Nov; 32(11):886-890. PubMed ID: 27223459
[TBL] [Abstract][Full Text] [Related]
3. Ovarian hyperstimulation syndrome inhibition by targeting VEGF, COX-2 and calcium pathways: a preclinical randomized study.
Kitsou C; Kosmas I; Lazaros L; Hatzi E; Euaggelou A; Mynbaev O; Tournaye H; Prapas N; Prapas I; Zikopoulos K; Galani V; Georgiou I
Gynecol Endocrinol; 2014 Aug; 30(8):587-92. PubMed ID: 24819316
[TBL] [Abstract][Full Text] [Related]
4. In vivo intrabursal administration of bioactive lipid sphingosine-1-phosphate enhances vascular integrity in a rat model of ovarian hyperstimulation syndrome.
Di Pietro M; Pascuali N; Scotti L; Irusta G; Bas D; May M; Tesone M; Abramovich D; Parborell F
Mol Hum Reprod; 2017 Jun; 23(6):417-427. PubMed ID: 28379469
[TBL] [Abstract][Full Text] [Related]
5. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
[TBL] [Abstract][Full Text] [Related]
6. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
Akman L; Sahin G; Erbas O; Aktug H; Akdogan A; Goker EN; Taskiran D; Tavmergen E
Gynecol Endocrinol; 2015 May; 31(5):369-73. PubMed ID: 25599748
[TBL] [Abstract][Full Text] [Related]
7. Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH.
van de Lagemaat R; Raafs BC; van Koppen C; Timmers CM; Mulders SM; Hanssen RG
Endocrinology; 2011 Nov; 152(11):4350-7. PubMed ID: 21896671
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model.
Quintana R; Kopcow L; Marconi G; Young E; Yovanovich C; Paz DA
Fertil Steril; 2008 Oct; 90(4 Suppl):1511-6. PubMed ID: 18166186
[TBL] [Abstract][Full Text] [Related]
9.
Zhang J; Huang J; He X; Li N; Miao Y; Li B; Shao X; Wang N
Gynecol Endocrinol; 2022 Feb; 38(2):170-175. PubMed ID: 34964405
[TBL] [Abstract][Full Text] [Related]
10.
Zhang J; Huang J; He X; Li N; Miao Y; Li B; Shao X; Wang N
Gynecol Endocrinol; 2022 Apr; 38(4):318-323. PubMed ID: 35285758
[TBL] [Abstract][Full Text] [Related]
11. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
[TBL] [Abstract][Full Text] [Related]
12. A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model.
Cenksoy C; Cenksoy PO; Erdem O; Sancak B; Gursoy R
Eur J Obstet Gynecol Reprod Biol; 2014 Mar; 174():86-90. PubMed ID: 24405730
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome.
Şahin N; Apaydın N; Töz E; Sivrikoz ON; Genç M; Turan GA; Cengiz H; Eskicioğlu F
Arch Gynecol Obstet; 2016 May; 293(5):1101-6. PubMed ID: 26690356
[TBL] [Abstract][Full Text] [Related]
14. Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam.
Saylan A; Arioz DT; Koken T; Dilek H; Saylan F; Yilmazer M
Acta Obstet Gynecol Scand; 2010 May; 89(5):692-9. PubMed ID: 20423279
[TBL] [Abstract][Full Text] [Related]
15. Successful reversal of ovarian hyperstimulation syndrome in a mouse model by rapamycin, an mTOR pathway inhibitor.
Liu W; Zhang C; Wang L; Huang X; Zhang J; He Y; Chen L; Li J
Mol Hum Reprod; 2019 Aug; 25(8):445-457. PubMed ID: 31329230
[TBL] [Abstract][Full Text] [Related]
16. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5.
Kitajima Y; Endo T; Nagasawa K; Manase K; Honnma H; Baba T; Hayashi T; Chiba H; Sawada N; Saito T
Endocrinology; 2006 Feb; 147(2):694-9. PubMed ID: 16269461
[TBL] [Abstract][Full Text] [Related]
17. Montelukast is effective in preventing of ovarian hyperstimulation syndrome; an experimental study.
Eskicioğlu F; Turan GA; Sivrikoz ON; Cengiz H; Zafer A; Akan Z; Sahin N; Yilmaz O; Yeşil H; Vatansever S
Ginekol Pol; 2015 Aug; 86(8):566-73. PubMed ID: 26492704
[TBL] [Abstract][Full Text] [Related]
18. Effect of GnRH-antagonist, mifepristone and letrozole on preventing ovarian hyperstimulation syndrome in rat model.
Luo J; Qi Q; Chen Y; Wang Y; Xie Q
Reprod Biomed Online; 2021 Feb; 42(2):291-300. PubMed ID: 33249057
[TBL] [Abstract][Full Text] [Related]
19. Effect of varying doses of tamoxifen on ovarian histopathology, serum VEGF, and endothelin 1 levels in ovarian hyperstimulation syndrome: an experimental study.
Pala Ş; Atilgan R; Ozkan ZS; Kavak SB; Ilhan N; Akpolat N; Sapmaz E
Drug Des Devel Ther; 2015; 9():1761-6. PubMed ID: 25848212
[TBL] [Abstract][Full Text] [Related]
20. Organ-specific production control of vascular endothelial growth factor in ovarian hyperstimulation syndrome-model rats.
Ishikawa K; Ohba T; Tanaka N; Iqbal M; Okamura Y; Okamura H
Endocr J; 2003 Oct; 50(5):515-25. PubMed ID: 14614207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]